Form 4: Stoke Therapeutics Executive Jonathan Allan Reports Stock Transactions
SEC Form 4 Filing
Jonathan Allan, General Counsel & Corp Sec of Stoke Therapeutics, reports acquisition of shares through stock options and employee stock purchase plan.
Summary
- On March 15, 2025, Jonathan Allan, General Counsel & Corp Sec of Stoke Therapeutics, acquired 7,475 shares of common stock through the vesting of restricted stock units (RSUs) and 6,000 shares of common stock through the vesting of additional restricted stock units.
- These transactions increased his direct holdings to 35,776 shares.
- The reported total includes an aggregate 825 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects routine stock transactions by an executive. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Positives
- The acquisition of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transactions have a minor positive impact on shareholders as it shows confidence from an insider.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Initial vesting date for 1/4 of the shares related to one of the restricted stock unit awards. |
| 03/15/2025 | Date of the reported transactions: vesting of RSUs and acquisition of shares through the Employee Stock Purchase Plan. |
| 03/15/2025 | Initial vesting date for 1/4 of the shares related to one of the restricted stock unit awards. |
| 03/15/2027 | Expiration date for the restricted stock units related to 7,475 shares. |
| 03/15/2028 | Expiration date for the restricted stock units related to 6,000 shares. |
| 03/18/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.